PBC team and labs take shape
To get the PBC established, Center Director, Dr. Vidadi Yusibov, along with Research Fellows Dr. Victor Wroblewski and Dr. Steven Haney, hired staff scientists and research assistants in 2018,, with additional hiring underway.
The PBC laboratories are currently being equipped and outfitted with completion anticipated in early 2019, allowing research activities to ramp-up between January and April 2019. As these activities gain momentum, the center will increase its visibility and outreach to partners in Indiana and beyond.
This initial phase starts a five-year plan for the PBC to set strategic priorities that follow antibody discovery with integrated capabilities for preclinical assessment and clinical lead development in collaboration with academic researchers and industrial customers.
This capacity is facilitated by the significant experience of the leadership team in the development of biotherapeutics and addresses a gap in the development efforts of academic centers and research hospitals.
Complementing IBRI research
To complement and support the IBRI’s other research areas, the PBC will also focus on the development of new therapies for diabetes and other cardio-metabolic diseases while retaining the flexibility to capture opportunistic approaches in other diseases when funding is available.